In fact, NSCLC patients with high PD-L1 expression exhibit poor overall survival41 and anti-PD-L1 and/or anti-PD-1 are now being used to treat many forms of cancer42,43, although only approximately 20% of patients respond to this type of treatment. This evidence concerns the gene CD274 and non-small cell lung carcinoma.